Grant ID RP240272
Awarded On February 21, 2024
Title The epigenetic impact and therapeutic opportunity of AR directed therapy for DSRCT
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Joseph Ludwig
Cancer Sites Childhood and Adolescent, Sarcoma
Contracted Amount $1,398,788*

*Pending contract negotiation

Lay Summary

Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma type that kills more than sixty, mostly male children and young adults in the United States each year. Half of these patients receive care at MD Anderson, but no curative therapies exist, and most patients die within five years of diagnosis despite specialized multidisciplinary treatment. Though the causative EWS-WT1 fusion protein (FP) is expressed in every patient's tumor, it isn't targetable. As a work-around, one approach is to minimize the FP's adverse tumor-promoting downstream effects. Toward that end, our lab and others have recently discovered that the androgen receptor (AR), more commonly known for its role in p...

Read More